| Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
| 26/09/2024 | 22:14 | Edgar (US Regulatory) | Form 144 - Report of proposed sale of securities | NASDAQ:RXRX | Recursion Pharmaceuticals Inc |
| 19/09/2024 | 23:48 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:RXRX | Recursion Pharmaceuticals Inc |
| 19/09/2024 | 22:27 | Edgar (US Regulatory) | Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material | NASDAQ:RXRX | Recursion Pharmaceuticals Inc |
| 17/09/2024 | 12:03 | Edgar (US Regulatory) | Form PREM14A - Preliminary proxy statements relating to merger or acquisition | NASDAQ:RXRX | Recursion Pharmaceuticals Inc |
| 03/09/2024 | 14:01 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:RXRX | Recursion Pharmaceuticals Inc |
| 03/09/2024 | 14:00 | GlobeNewswire Inc. | Recursion Announces Phase 2 Data of REC-994, a First-in-Disease Investigational Treatment for Symptomatic Cerebral Cavernous Malformation (CCM), has Met its Primary Endpoint of Safety and Tolerability | NASDAQ:RXRX | Recursion Pharmaceuticals Inc |
| 09/08/2024 | 11:44 | IH Market News | TSMC July Revenue Surges 45%, Nasdaq Accelerates Penny Stock Delistings, Moody’s Downgrades Intel to BAA1, and More | NASDAQ:RXRX | Recursion Pharmaceuticals Inc |
| 08/08/2024 | 20:41 | GlobeNewswire Inc. | CORRECTION - Recursion Provides Business Updates and Reports Second Quarter 2024 Financial Results | NASDAQ:RXRX | Recursion Pharmaceuticals Inc |
| 08/08/2024 | 14:09 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | NASDAQ:RXRX | Recursion Pharmaceuticals Inc |
| 08/08/2024 | 13:39 | GlobeNewswire Inc. | Recursion and Exscientia Enter Definitive Agreement to Create a Global Technology-Enabled Drug Discovery Leader with End-to-End Capabilities | NASDAQ:RXRX | Recursion Pharmaceuticals Inc |
| 08/08/2024 | 13:30 | GlobeNewswire Inc. | Recursion Provides Business Updates and Reports Second Quarter 2024 Financial Results | NASDAQ:RXRX | Recursion Pharmaceuticals Inc |
| 08/08/2024 | 07:32 | GlobeNewswire Inc. | Recursion updates L(earnings) call on August 8th to 8:30 am ET / 6:30 am MT | NASDAQ:RXRX | Recursion Pharmaceuticals Inc |
| 05/08/2024 | 22:01 | GlobeNewswire Inc. | Recursion to Report Second Quarter 2024 Business Updates and Financial Results on August 8th | NASDAQ:RXRX | Recursion Pharmaceuticals Inc |
| 13/07/2024 | 00:52 | Edgar (US Regulatory) | Form 4/A - Statement of changes in beneficial ownership of securities: [Amend] | NASDAQ:RXRX | Recursion Pharmaceuticals Inc |
| 27/06/2024 | 04:07 | GlobeNewswire Inc. | Recursion Announces Pricing of $200 Million Public Offering of Class A Common Stock | NASDAQ:RXRX | Recursion Pharmaceuticals Inc |
| 26/06/2024 | 22:06 | GlobeNewswire Inc. | Recursion Announces Proposed Offering of Class A Common Stock | NASDAQ:RXRX | Recursion Pharmaceuticals Inc |
| 24/06/2024 | 14:00 | GlobeNewswire Inc. | Recursion Gives Guidance on Seven Clinical Readouts within ~18 Months and Partnership Updates at Their Download Day | NASDAQ:RXRX | Recursion Pharmaceuticals Inc |
| 14/06/2024 | 23:12 | Edgar (US Regulatory) | Form 144/A - Report of proposed sale of securities: [Amend] | NASDAQ:RXRX | Recursion Pharmaceuticals Inc |
| 03/06/2024 | 15:00 | GlobeNewswire Inc. | Recursion to Participate in Upcoming Investor Conferences | NASDAQ:RXRX | Recursion Pharmaceuticals Inc |
| 29/05/2024 | 21:27 | GlobeNewswire Inc. | Power of Recursion OS on Display at Genome Scale in Nature Genetics Paper Detailing Potential Limitation of CRISPR Gene Editing Tool | NASDAQ:RXRX | Recursion Pharmaceuticals Inc |
| 24/05/2024 | 22:30 | GlobeNewswire Inc. | Recursion Appoints Robert Hershberg M.D., Ph.D, as New Chair of the Board | NASDAQ:RXRX | Recursion Pharmaceuticals Inc |
| 13/05/2024 | 11:00 | GlobeNewswire Inc. | Recursion Announces Completion of NVIDIA-Powered BioHive-2, the Largest Supercomputer in Pharmaceutical Industry | NASDAQ:RXRX | Recursion Pharmaceuticals Inc |
| 09/05/2024 | 22:01 | GlobeNewswire Inc. | Recursion Provides Business Updates and Reports First Quarter 2024 Financial Results | NASDAQ:RXRX | Recursion Pharmaceuticals Inc |
| 02/05/2024 | 14:00 | GlobeNewswire Inc. | Recursion to Report First Quarter 2024 Business Updates and Financial Results on May 9 | NASDAQ:RXRX | Recursion Pharmaceuticals Inc |
| 30/04/2024 | 14:00 | GlobeNewswire Inc. | Altitude Lab Secures Small Business Administration Growth Fund Accelerator Grant to Launch Horizon, a Commercialization Partnering Program | NASDAQ:RXRX | Recursion Pharmaceuticals Inc |
| 16/04/2024 | 14:00 | GlobeNewswire Inc. | Recursion Appoints Najat Khan, PhD, as Chief R&D Officer and Chief Commercial Officer | NASDAQ:RXRX | Recursion Pharmaceuticals Inc |
| 02/04/2024 | 14:00 | GlobeNewswire Inc. | Recursion to Participate in Upcoming Investor Conference | NASDAQ:RXRX | Recursion Pharmaceuticals Inc |
| 26/03/2024 | 13:00 | GlobeNewswire Inc. | Recursion Publishes Annual Environmental, Social and Governance Report | NASDAQ:RXRX | Recursion Pharmaceuticals Inc |
| 11/03/2024 | 09:00 | GlobeNewswire Inc. | Recursion Announces Plans to Open New Office in London | NASDAQ:RXRX | Recursion Pharmaceuticals Inc |
| 01/03/2024 | 20:58 | GlobeNewswire Inc. | Recursion Hosts Second Annual Rare Disease Day Events for Utah’s Rare Disease Community | NASDAQ:RXRX | Recursion Pharmaceuticals Inc |